Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CureVac NV CVAC

Healthcare Biotechnology
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Recent & Breaking News (NDAQ:CVAC)

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Accesswire 2 days ago

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Accesswire 2 days ago

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Accesswire 2 days ago

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Accesswire 8 days ago

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Accesswire 10 days ago

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Accesswire April 4, 2024

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Accesswire January 5, 2024

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Accesswire December 19, 2023

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

Accesswire November 14, 2023

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

Accesswire November 1, 2023

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

Accesswire September 12, 2023

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

Accesswire August 17, 2023

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

Accesswire August 1, 2023

CureVac Announces Update to the Management Team

Accesswire July 14, 2023

CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

Accesswire July 13, 2023

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

Accesswire June 20, 2023

CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board

Accesswire June 20, 2023

CureVac Announces Voting Results of General Meeting

Accesswire June 19, 2023

CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

Accesswire May 30, 2023

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

Accesswire May 19, 2023